

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

#### **Overview**

The use, possession, sale, cultivation, and transportation of cannabis in the United States under federal law is illegal but the federal government has announced that if a state wants to pass a law to decriminalize cannabis for recreational or medical use, they can do so, but they need to have a regulation system in place for cannabis. As of July 1, 2015, 23 states and the District of Columbia have legalized medical marijuana. This legalization began with the state of California back in 1996, with Maryland, Minnesota and New York recently joining the list in 2014. Currently, the use of both recreational and medical marijuana has been entirely legalized in the states of Colorado, Washington, Alaska and Oregon, along with the District of Columbia.<sup>i</sup>

In addition to these states and the District of Columbia, there are another 17 states with limited access marijuana product laws (low THC/high CBD-Cannabidiol).<sup>ii</sup>

At the present time, seven states are preparing for legalization pushes, with potential ballot initiatives set for 2016. These states include Massachusetts, California, Missouri, Hawaii, Maine, Nevada, and Arizona.

With the push to legalize cannabis, both for recreational and medical use, sweeping across the United States, an argument could be made that companies and entrepreneurs in a cannabis-based business could see a bright future. Cannabis grows operations and dispensaries are flush with cash with this ongoing legalization and state tax receipts have increased substantially. However, because of federal laws such as the Bank Secrecy Act of 1970 and anti-money-laundering statutes enforced by the U.S. Treasury's Financial Crimes Enforcement Network (FinCEN), banks are blocked from even distantly connecting themselves with activity prohibited by federal law, even in states where activity is legal.<sup>iii</sup>

In the US, legal marijuana is competing strongly with the tobacco and e-cigarette industries. The cannabis market was valued at \$2.7 billion in 2014 and expects to grow 32% in 2015 to \$3.6 billion in 2015. As 2019 approaches, experts are predicting that if all states legalize the product, then the industry should rise to about \$11 billion, which would make marijuana one of the largest and fastest growing industries in the country.<sup>iv</sup>

There is plenty of information to be found on the cannabis industry on the Internet. There are also plenty of marijuana-focused companies currently trading. MarijuanaStocks.com currently has 82 of these on their Focus List along with many interesting marijuana articles, marijuana stock news headlines, stock prices, etc..<sup>v</sup>

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

There is a growing business opportunity in marijuana, revenues to capture, and profits to be harvested. As with any stock investment, putting time into doing the necessary due diligence, reading the financial statements, understanding the analytics and ratios, performing the competitive analysis among the companies doing business in similar areas, etc... will give an investor a better idea of which company is best of breed.

This article summarizes four specific companies in the industry, including a summary of the business and operations, recent news and guidance given by the company, and a one-year stock chart. These companies include:

- **AeroGrow International, Inc. (AERO)**
- **GW Pharmaceuticals plc (GWPH)**
- **Medbox, Inc (MDBX)**
- **Cannabis Science, Inc (CBIS)**

At the very end of this overview, a few of the risks involved with investing are listed and personal guidance is given on each of the four stocks reviewed.

#### **AeroGrow International, Inc. (AERO – OTCQB)**

Current Price - \$1.40 (as of market close 08/31/2015)

Market Capitalization - \$10.35 million

#### **Summary**

AeroGrow International, Inc is the creator, manufacturer and marketer of Miracle-Gro AeroGardens, a comprehensive line of extraordinary soil-free indoor gardens. Headquartered in Boulder, Colorado, AeroGrow is the leader in the rapidly growing indoor gardening market with a commitment to helping people successfully grow healthy, fresh food - and more - regardless of season, location, or experience.

The Miracle-Gro AeroGarden line is sold through multiple channels, including:

- On-line retail sales through .com retailers such as Amazon.com, Costco.com, Walmart.com and others
- In-store retail sales through retailers such as Costco, The Home Depot, True Value, Walmart, and others
- Direct-to-consumer sales using a variety of digital, social and print media to drive sales at [www.aerogarden.com](http://www.aerogarden.com).

All Miracle-Gro AeroGardens feature proprietary NASA tested technology which helps consumers to garden indoors, year round, with no dirt, no weeds and no green thumb needed. Miracle-Gro AeroGardens are complete indoor gardening systems with built in, full spectrum Grow Lights,

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

patented hydroponic nutrients and easy-to-use control panels that automate key garden functions for guaranteed success.

Since introducing the first AeroGarden in March 2006, AeroGrow has expanded the product line to include multiple gardens with different price points and consumer benefits. From small to tall and from simple to sophisticated, there's an AeroGarden for every consumer regardless of their aptitude or gardening experience.

AeroGrow also develops, manufactures and markets a variety of consumable products for use in its gardens including Seed Kits, Grow Lights, hydroponic nutrients and accessory products. These products, in conjunction with the sale of additional AeroGardens to past purchasers, provide ongoing, repeat sales to the Company and generate continued engagement and interest from the user base. These repeat sales account for approximately 50% of corporate revenues in the Company's direct-to-consumer business.<sup>vi</sup>

#### **Recent News and Analysis**

- Aug. 10, 2015 – AeroGrow Reports Results for the First Quarter Ended June 30, 2015<sup>vii</sup>
  - Revenues for the three months ended June 30, 2015 were \$1,569,000 compared to \$1,683,000 for the same period in 2014.
  - For the first quarter 2015, costs of revenues were \$1,088,000, total operating expenses were \$1,438,000, other expenses were \$43,000, leaving the company with a total net loss of (\$1,000,000) or (\$0.15) per share. The total net loss for the first quarter 2014 was (\$1,097,000) or (\$0.18) per share.
  - On the balance sheet, as of June 30, 2015, the Company has \$486,000 in cash, cash equivalents and marketable securities, compared to \$1,030,000 as of March 31, 2015.
  - On the statement of cash flows, for the three months ended June 30, 2015, net cash provided by (used in) operating activities totaled (\$436,000), compared to (\$563,000) for the three months ended June 30, 2014.

- Jul. 9, 2015 – AeroGrow Finalizes \$6.0 Million Term Loan for Scotts Miracle-Gro<sup>viii</sup>

This funding will provide general working capital to support anticipated growth as the Company expands its retail and its direct-to-consumer sales channels and new product introductions. The proceeds, which total up to \$6.0 million, will be made available as needed in three advances up to \$2.0 million, \$2.5 million, and \$1.5 million in July, August and September, respectively with a due date of April 15, 2016.

AeroGrow's CEO (J. Michael Wolfe) published a Shareholder's Letter that was included with the annual report filing. This letter recaps the fiscal year 2015 (key initiatives and key developments), a look head for plans for fiscal year 2016 (growth, innovation, and

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

sustainability..., along with a description of seven key initiatives), a look beyond fiscal year 2016, and a summary and recognition of the progress the company has made turning the business around and beginning to grow.<sup>ix</sup>

#### **AeroGrow International, Inc. (AERO) Guidance**

AeroGrow has revenues and products in their pipeline for indoor growing, but the majority of the revenues come during the months of the Christmas holiday season. Their relationship with Scotts Miracle-Gro (SMG-NYSE) is definitely important piece of their future success, given the recent funding arrangement. Demand for the AeroGrow product is reported to be increasing, and this is not a product singularly relying on the legalization of medical and/or recreational cannabis. Littany Lane Investments remains optimistic on the prospects for AeroGrow. The holiday season is quickly approaching and growth in revenues will be instrumental in the ongoing success of this company.

# Littany Lane Investments

## Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)

AeroGrow International Inc AERO:OTCQB

Get Quote

Charts

GO

Recent Quotes

Set Alert

Options Chain

LAST PRICE **\$1.40** TODAY'S CHANGE **0.00(0.00%)** BID (SIZE) **\$0.00 (0)** ASK (SIZE) **\$0.00 (0)** DAY LOW / HIGH **\$1.33 - 1.41** VOLUME **4.2 K**

BUY

SELL

NASDAQ Closing Price as of 12:27PM ET 8/31/15

Snapshot Charts News Options Earnings Fundamentals Financials Insiders

Download historical data

1 Day 5 Day 1 Month 3 Month YTD 1 Year 3 Year 5 Year Max Custom Frequency: Daily My Charts: Select Chart Save Reset

Upper Indicators

Lower Indicators

Events

Compare

Chart Style

Tools

Bollinger Bands (20,2)



Volume+ (Thousands) Close Up (1.3M) Close Down (2.2M) EMA(13)

Options



RSI (14)

Options



x

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

#### **GW Pharmaceuticals plc (GWPH – NASDAQ)**

Current Price - \$106.35 (as of market close 08/31/2015)

Market Capitalization - \$2.17 billion

#### **Summary**

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex<sup>®</sup>, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex<sup>®</sup>, which is in Phase 3 clinical development for the treatment of Dravet syndrome and the treatment of Lennox-Gastaut syndrome. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 clinical development for glioma, type 2 diabetes, and schizophrenia.<sup>xi</sup>

#### **Recent News and Analysis**

- Aug. 6, 2015 – GW Pharmaceuticals plc Reports Third Quarter 2015 Financial Results and Operational Progress<sup>xii</sup>
  - Revenues for the three months ended June 30, 2015 were \$13,550,000 compared to \$13,019,000 for the same period in 2014..., and total revenues for the nine months ended June 30, 2015 were \$36,030,000 compared to \$38,702,000 for the same nine month period in 2014.
  - For the third quarter 2015, costs of revenues were \$1,132,000, total operating expenses were \$51,311,000, other income (expenses) were \$5,249,000, leaving the company with a total net loss of (\$33,644,000) or (\$0.133) per share. The total net loss for the third quarter 2014 was (\$11,850,000) or (\$0.055) per share. Total net loss for the nine months ended June 30, 2015 was (\$50,765,000) or (\$0.21) per share, compared to (\$25,556,000) or (\$0.127) per share for the same nine month period in 2014.
  - On the balance sheet, as of June 30, 2015, the Company has \$398,927,000 in cash, cash equivalents and marketable securities, compared to \$266,788,000 as of September 30, 2014.
  - On the statement of cash flows, for the nine months ended June 30, 2015, net cash provided by (used in) operating activities totaled (\$46,332,000), compared to (\$12,643,000) for the nine months ended June 30, 2014.

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

- Aug. 6, 2015 - GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)<sup>xiii</sup>
- Jun. 11, 2015 – GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome<sup>xiv</sup>
- May 19, 2015 – GW Appoints Senior Executive to President, North America and Relocates CEO to the U.S.<sup>xv</sup>

Julian Gangolli joined GW in the newly created position of President, North America, and has been appointed to the GW Board of Directors. Previously, Mr. Gangolli was President of the North American Pharmaceutical division of Allergan Inc., with responsibility for a 1,400-person integrated commercial operation with sales exceeding \$3.8 billion in 2014. GW also announced the relocation of the Company's CEO, Justin Gover, to the U.S. Together, Mr. Gangolli and Mr. Gover will lead GW's growth in the U.S. and prepare for the expected NDA submission and build the in-house U.S. commercial infrastructure required for a successful commercial launch of Epidiolex.

- May 15, 2015 – GW Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares<sup>xvi</sup>

GW successfully completed a U.S. follow-on offering on the NASDAQ Global Market issuing a total of 1,840,000 American Depositary Shares ("ADSs") at a price of \$112.00 per ADS. This total included the full exercise of the underwriter's option to purchase an additional 240,000 ADSs and resulted in total net proceeds after expenses of approximately \$193.3 million (£127.5 million). The funds raised in this offering are primarily intended to support further expansion of GW's Epidiolex manufacturing capability and build-up of inventory in preparation for U.S. launch, if Epidiolex is approved; clinical development of other orphan indication opportunities for Epidiolex, with an initial focus on Tuberous Sclerosis Complex; the advancement of other pipeline opportunities, including an intravenous CBD formulation in the treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE); pre-launch commercialization activities for Epidiolex in the United States; and for other general corporate purposes.

#### **GW Pharmaceuticals plc (GWPH) Guidance**

Consensus estimates for the fourth quarter 2015 (September 30) is for a loss of \$1.37, with an annual loss for the year ended September 30, 2015 expected to be \$3.70. The first quarter of the next fiscal year (December 31, 2015) is expected to come in at a net loss of \$1.53, with the projected fiscal year loss (year ended September 30, 2016) to come in at \$6.32.<sup>xvii</sup>

# Littany Lane Investments

## Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)

This company has medical marijuana products in their pipeline, along with an FDA fast track status on a certain treatment. The company does have revenues; however they are not net income positive. Additionally, the company has cash on hand to support additional research and their daily operations. Analysts at Morgan Stanley recently initiated coverage on this company with a base case target price of \$150 and a bull case target of \$195 to go with an overweight rating. Publicity for medical marijuana companies is growing; however the industry's future is still uncertain with the discrepancy between federal and state laws. Littany Lane Investments is optimistic on the prospects for GW Pharmaceuticals in a growing and developing market..., and will continue to monitor developments.





## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

#### **Medbox Inc. (MDBX – OTCQB)**

Current Price - \$0.11 (as of market close 08/31/2015)

Market Capitalization - \$10.04 million

#### **Summary**

Medbox, Inc., a leader in the rapidly emerging cannabis sector, provides specialized services to operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved. Through trusted clients and affiliates, the company promotes efficient, consistent, high quality products that are priced right, readily available and safely packaged.

In addition, through its wholly owned subsidiary, Vaporfection International, Inc., Medbox sells a line of vaporizer and accessory products online and through distribution partners.<sup>xix</sup>

#### **Recent News and Analysis**

- Aug. 27, 2015 – Medbox Enters State of Washington, Signs Agreement to Consult on Opening of New Marijuana Dispensary<sup>xx</sup>

Under the agreement, Medbox will provide specialized consulting services to the principals and operators of the Fweedom Collective medical dispensary in Seattle for the opening of a new 502 recreational retail dispensary in Mt. Vernon, WA. The new dispensary is scheduled to be operational in the first half of 2016.

- Aug. 26, 2015 – Medbox and Shareholder Group Led by Founder Amend Voting Agreement<sup>xxi</sup>

VM Group (a shareholder group led by its founder, P. Vincent Mehdizadeh) executed a majority shareholder consent to eliminate certain super voting rights from the company's Series A Preferred Stock, and further deferred VM Group's right to appoint a director to the company's board. The amendment also extended the expiration date of the voting agreement to July 2018, and the company agreed to accelerate the remaining \$328,877 payments due on a promissory note to a member of VM Group. VM Group voluntarily cancelled and retired all of its two million Medbox preferred shares and three million of its Medbox common shares, effectively relinquishing VM Group's majority voting position.

- Aug. 25, 2015 – Medbox Completes \$4.5 Million Financing<sup>xxii</sup>
- Aug. 20, 2015 – Medbox Engages Israel-Based Medical Marijuana Consultancy, As Company Prepares to Enter Cultivation Market<sup>xxiii</sup>

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

After 30 years of cannabis industry experience in the United States, Israel and Europe, Avner Barak, co-founder of Cannaguru Agrotechnic Consulting Ltd. (CAC), recently was brought on to consult with Medbox on proprietary true-to-type genetics, expert cultivation techniques and business development opportunities. Barak is currently co-leading Canndoc, which is one of eight licensed growers supplying medicine to thousands of Israeli patients and has operated a medical cannabis farm in Israel since 2009 for the Israel Ministry of Health.

- Aug. 14, 2015 – Medbox Reports 2015 Second Quarter Financial Results<sup>xxiv</sup>
  - Revenues for the three months ended June 30, 2015 were \$84,365, compared to \$360,105 for the same period in 2014.
  - For the second quarter 2015, costs of revenues were \$867,025, total operating expenses were \$5,236,018, other expenses were \$5,217,074, leaving the company with a total net loss of (\$11,394,908) or (\$0.32) per share. The total net loss for the second quarter 2014 was (\$1,347,784) or (\$0.04) per share.
  - On the balance sheet, as of June 30, 2015, the Company has \$749,084 in cash, cash equivalents and marketable securities, compared to \$596,434 as of December 31, 2014.
  - On the statement of cash flows, for the six months ended June 30, 2015, net cash provided by (used in) operating activities totaled (\$4,166,781), compared to (\$1,807,451) for the six months ended June 30, 2014.
- Jul. 6, 2015 – Medbox Promotes Jeff Goh to President and Interim CEO As Company Embarks on Next Stage of Development<sup>xxv</sup>

Goh, 51, has been Chief Operating Officer of Medbox since April 2015 and prior to that served as a consultant since August 2014. He brings to the company more than three decades of relevant experience in executive management capacities with Frito Lay (PepsiCo) and Procter & Gamble, as well as helping smaller companies scale their business models.

In his added roles at Medbox, Goh succeeds Guy Marsala, 64, who joined Medbox in July 2014 to help guide the company through a corporate and financial transition period, setting the stage for a new and expanded business model. Marsala will also no longer serve on Medbox's board of directors.

- Dec. 30, 2014 and Mar. 9, 2015 - Medbox to Restate Financial Results<sup>xxvi xxvii</sup>

Medbox plans to amend and restate its financial statements for the first three quarters of 2014, the year 2013, all quarterly reports of 2013, the year 2012, and Q1, Q2 and Q3 of 2012. Most of the items amended and/or restated pertained to improper revenue


# Littany Lane Investments

## Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)

recognition, although one involved improperly capitalizing inventory which understated cost of sales.

### Medbox, Inc (MDBX) Guidance

This is a company with declining revenues, while continuing to burn through cash for operations. Additionally, they recently went through a change in the management group, their financial statements for multiple quarters have been amended and restated, and they made a change in their CPA firm. While their CEO Jeffrey Goh is optimistic on the company (what CEO is not optimistic in shareholder letters?), at the current time, Littany Lane Investments is not an advocate for purchase of an equity position in this name.



## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

#### **Cannabis Science, Inc. (CBIS - OTCQB)**

Current Price - \$0.03 (as of market close 08/31/2015)

Market Capitalization - \$42.44 million

#### **Summary**

Cannabis Science alleviates suffering and promotes health through cannabinoid science. A pioneering biotech company, Cannabis Science creates cannabinoid-based extract formulations for various medical conditions, including more than 8 different types of Cancer.

Each individual one of these formulations has revenue and earnings potential in the hundreds of millions of dollars based on the current global pharmaceutical industry. The potential revenue and earnings are combined with additional profit centers including an educational model, nutraceutical products, and a strategic partnership with MedBox® Solutions. These additional profit centers bring a higher level of confidence to realizing our overall financial strategy and plan to bring Cannabis Science into positive earnings per share by 2015.

The cannabinoid market and industry is best explained using the alcohol prohibition black market model in the 1920's, and then as a pharmaceutical retail market in the 1930's.

The cannabinoid market is estimated at \$30-\$50 billion. Internal estimates raise that number to \$74 billion upon speculation of the Federal Medical Cannabis Program in 2017.

Cannabis Science's President Emeritus, Dr. Robert Melamede, Ph.D., is focused on the quantum physics relationship with biology, and the role the cannabinoid strain plays in the string of life. His research and science of the cannabinoid system along with the relationship between the endocannabinoid system and phytocannabinoids is pioneering. The Cannabis Science Scientific Advisory Board is comprised of several doctors who embrace and support Dr. Melamede's vision. Board members are all considered global leaders.

Cannabis Science's executive management team is built through a partnership of independent consultants whose interests are aligned with the success of shareholders and Cannabis Science. This model and their executive management plan have allowed Cannabis Science to attract strategic partnerships that generate revenues, as with Vincent Mehdizadeh, from MedBox. It also has allowed Cannabis Science to strengthen the services of the company both with investors through Robert Kane, Investor Relations Manager, and with patients.

Cannabis Science is the first publicly traded cannabinoid company on the market, whose symbol is CBIS, and is the only publicly traded company in existence that is involved in cannabinoid-extract based formulations. This model and leadership position is of great value as the company matures over the next twenty years and expands globally into a potential billion dollar biotech global leader.

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

In conclusion, Cannabis Science is a company doing the right things, for the right reasons, with the right people, a company started by someone who was ill and found a way to heal themselves. That person shared their solution with others and they have shared with hundreds of millions of patients who are suffering; chronic pain patients, cancer patients, MS patients, soldiers and veterans with PTSD, those who are terminally ill, and patients with dozens of other conditions are now all aware of the medicinal value of cannabinoid. Now is simply the best opportunity for Cannabis Science to help and heal those who are suffering through their formulations and services.<sup>xxix</sup>

#### **Recent News and Analysis**

- Jul. 28, 2015 – Cannabis Science Reports 2015 First Quarter Financial Results<sup>xxx</sup>
  - The company had no revenues to report for the first three months ended March 31, 2015, compared to \$1,031 for the same three month period in 2014
  - For the first quarter 2015, total operating expenses were \$4,236,544 and other expenses were \$104,926, leaving the company with a total net loss attributable to common shareholders (\$4,341,470) or (\$0.00) per share. The total net loss for the first quarter 2014 was (\$5,287,247) or (\$0.01) per share.
  - On the balance sheet, as of March 31, 2015, the Company has \$37,524 in cash, cash equivalents and marketable securities, compared to \$10,061 as of December 31, 2014.
  - On the statement of cash flows, for the three months ended March 31, 2015, net cash provided by (used in) operating activities totaled (\$273,677), compared to (\$74,515) for the three months ended March 31, 2014.
  - Going Concern noted on Form 10-Q for the quarter ended March 31, 2015 and also included on the Form 10-K for the year ended December 31, 2014.<sup>xxxi</sup>

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company reported an accumulated deficit of \$100,574,615 and had a stockholders' deficit of \$3,159,100 at September 30, 2014.

In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital. At September 30, 2014, the Company had insufficient operating revenues and cash flow to meet its financial obligations. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

- Jul. 16, 2015 – Cannabis Science Signs Research & Distribution Agreement for California and Announces Guidance for Its New Product Releases in California and International Cannabinoid Research Operations<sup>xxxii</sup>

The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program.

CSRF will be responsible for all of the CBIS State-by-State initiatives followed by Colorado, Washington, and subsequent States as scheduled products become available for distribution. The much-anticipated California release includes new extract products that will be the first in line and scheduled for release next week in California. This first batch of extracts will be followed by the second batch consisting of pill type capsules for oral consumption. These initial products will be available in a variety of dosage strengths, and subsequent products will be released in succession throughout the State of California.

- May 27, 2015 - Cannabis Science Brings CS-TATI-1 to the FDA with Historic Collaborative Drug Development Deal With IGXBio and Its GenePro®, a DNA-Based Immunotherapeutic that Recently Received FDA Approval to Enter into Human Trials<sup>xxxiii</sup>

Cohen Grassroots Research, Inc. published a research report on Cannabis Science back on March 13, 2015 that provides a lot of information on the company, including a price index target (\$0.19), an executive summary, industry overview, and a comparative analysis of competitors in the industry.<sup>xxxiv</sup>

#### **Cannabis Science, Inc (CBIS) Guidance**

This is a company with no revenues, little cash, continuing operating expenses, and their quarterly and annual financial statements documenting a “going concern” issue in the notes to the financial statements. In this situation, the company continues to seek outside financing sources in order to continue operations. While there may be optimism from management and also a potential from growth in cannabis industry, at the current time, Littany Lane Investments is not an advocate for purchase of an equity position in this name.

# Littany Lane Investments

## Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)

Cannabis Science Inc CBIS:OTC Pink - Limited  
Information

Get Quote

Charts

GO

Recent Quotes

Set Alert

Options Chain

LAST PRICE **\$0.033** TODAY'S CHANGE **-0.005(12.47%)** BID (SIZE) **\$0.00 (0)** ASK (SIZE) **\$0.00 (0)** DAY LOW / HIGH **\$0.0315 - 0.0385** VOLUME **18.7 M**

BUY

SELL

NASDAQ Closing Price as of 3:59PM ET 8/31/15

Snapshot

Charts

News

Options

Earnings

Fundamentals

Financials

Insiders

Download historical data

1 Day

5 Day

1 Month

3 Month

YTD

1 Year

3 Year

5 Year

Max

Custom

Frequency: Daily

My Charts: Select Chart

Save

Reset

Upper Indicators

Lower Indicators

Events

Compare

Chart Style

Tools

Bollinger Bands (20,2)




Volume+ (Millions) Close Up (583.6M) Close Down (684.5M) EMA(13)

Options



RSI (14)

Options



xxxxv

# Littany Lane Investments

## Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)

### Risk Factors to Consider

There are many risks to consider when investing in small-capitalization stocks, including the following:

- Government approval and regulation
- Lack of adequate capital, including less financial resources and limited access to capital
- Inaccurate estimates of the market
- Competition within the industry
- Small-cap stocks have lower trading liquidity
- Small companies may not have long operating histories or proven business models
- Less information may be publicly available

---

#### Sources

- <sup>i</sup> <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>
- <sup>ii</sup> <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>
- <sup>iii</sup> <http://www.institutionalinvestor.com/Article/3483756/Asset-Management/Cannabis-Economy-Lags-Behind-Legalization.html?LS=EMS1199042#.VeRorW7ZX7Z>
- <sup>iv</sup> <http://seekingalpha.com/instablog/11367801-lancelot-tucker/3822116-is-the-cannabis-market-growing-in-the-us>
- <sup>v</sup> <http://marijuanastocks.com>
- <sup>vi</sup> <http://www.aerogrow.com/investors/>
- <sup>vii</sup> <http://www.aerogrow.com/investors/>
- <sup>viii</sup> <http://www.aerogrow.com/investors/>
- <sup>ix</sup> <http://www.aerogrow.com/investors/>
- <sup>x</sup> <https://research.trading.com/research/quotes/stock-charts.asp?mcsymbol=AERO>
- <sup>xi</sup> <http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=926229>
- <sup>xii</sup> <http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=926229>
- <sup>xiii</sup> <http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=926193>
- <sup>xiv</sup> <http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=917502>
- <sup>xv</sup> <http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=913807>
- <sup>xvi</sup> <http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=913458>
- <sup>xvii</sup> <http://finance.yahoo.com/q/ae?s=GWPH+Analyst+Estimates>
- <sup>xviii</sup> <https://research.trading.com/research/quotes/stock-charts.asp?mcsymbol=GWPH>
- <sup>xix</sup> <http://ir.thedisdispensingolution.com/>
- <sup>xx</sup> <http://ir.thedisdispensingolution.com/press-releases/detail/2043/medbox-enters-state-of-washington-signs-agreement-to>
- <sup>xxi</sup> <http://ir.thedisdispensingolution.com/press-releases/detail/2042/medbox-and-shareholder-group-led-by-founder-amend-voting>
- <sup>xxii</sup> <http://ir.thedisdispensingolution.com/press-releases/detail/2041/medbox-completes-4-5-million-financing>
- <sup>xxiii</sup> <http://ir.thedisdispensingolution.com/press-releases/detail/2040/medbox-engages-israel-based-medical-marijuana-consultancy>
- <sup>xxiv</sup> <http://ir.thedisdispensingolution.com/press-releases/detail/2039/medbox-reports-2015-second-quarter-financial-results>
- <sup>xxv</sup> <http://ir.thedisdispensingolution.com/press-releases/detail/2035/medbox-promotes-jeff-goh-to-president-and-interim-ceo-as>
- <sup>xxvi</sup> <http://seekingalpha.com/news/2199785-medbox-to-restate-financial-statements>
- <sup>xxvii</sup> <http://seekingalpha.com/news/2355546-medbox-adds-to-list-of-restatement-periods>
- <sup>xxviii</sup> <https://research.trading.com/research/quotes/stock-charts.asp?mcsymbol=MDBX>
- <sup>xxix</sup> <http://www.cannabisscience.com/index.php/investors/investor-information>
- <sup>xxx</sup> <http://irdirect.net/filings/viewer/index/1024626/000151712615000177/>
- <sup>xxxi</sup> <http://irdirect.net/filings/viewer/index/1024626/000151712614000362/>
- <sup>xxxii</sup> <http://www.cannabisscience.com/index.php/news-media/cbis-latest-news/712-cannabis-science-signs-research-distribution-agreement-for-california-and-announces-guidance-for-its-new-product-releases-in-california-and-international-cannabinoid-research-operations>
- <sup>xxxiii</sup> <http://www.cannabisscience.com/index.php/news-media/cbis-latest-news/710-cannabis-science-brings-cs-tati-1-to-the-fda-with-historic-collaborative-drug-development-deal-with-igxbio-and-its-gene-pro-a-dna-based-immunotherapeutic-that-recently-received-fda-approval-to-enter-into-human-trials>
- <sup>xxxiv</sup> [http://www.cannabisscience.com/downloads/cbis-analyst-report\\_cohengrassrootsresearch\\_03-14-2015.pdf](http://www.cannabisscience.com/downloads/cbis-analyst-report_cohengrassrootsresearch_03-14-2015.pdf)
- <sup>xxxv</sup> <https://research.trading.com/research/quotes/stock-charts.asp?mcsymbol=CBIS>



## ***Littany Lane Investments***

### ***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies (AERO, GWPH, MDBX, and CBIS)***

---

Disclosures: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from BroadStreetAlerts). The author has no business relationship with any company whose stock is mentioned in this article.

The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Jeffrey S. Grossman to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor's particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

#### **FORWARD-LOOKING STATEMENT**

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

#### **COMPLIANCE PROCEDURE**

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Jeffrey S. Grossman. An outsourced research services provider represented by Jeffrey S. Grossman, provided Broad Street Alerts this article or report. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Jeffrey S. Grossman. All parties responsible for the creation and dissemination of this report do not engage in high frequency trading.

#### **NO WARRANTY OR LIABILITY ASSUMED**

Broad Street Alerts has not been compensated for the creation or dissemination of this report. Broad Street Alerts is not responsible for any error, mistake or shortcoming which may be occasioned at the time of printing of this document. Broad Street Alerts does not hold any positions in companies mentioned. No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. The included information is subject to change without notice.

Broad Street Alerts is the party responsible for hosting the full analyst report. Broad Street Alerts has compensated Jeffrey S. Grossman two hundred and fifty dollars for the right to disseminate this report. Information in this report is fact checked and produced on a best efforts basis by Jeffrey S. Grossman.

## ***Littany Lane Investments***

***Medical Marijuana and Investing in Pot – Equity Overview of Four Companies  
(AERO, GWPH, MDBX, and CBIS)***

---